This was the stock's third consecutive day of gains.

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately. Vertex Pharmaceuticals' suzetrigine is an investigational pain ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price ...

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.